Related by context. All words. (Click for frequent words.) 77 Gleevec 76 rituximab 75 dasatinib 74 nilotinib 74 sunitinib 73 erlotinib 73 docetaxel 73 bortezomib 72 lamivudine 72 trastuzumab 72 topotecan 72 gefitinib 72 sorafenib 72 cetuximab 71 gemcitabine 71 imatinib therapy 71 chlorambucil 71 etanercept 71 imatinib Gleevec 71 zoledronic acid 70 infliximab 70 Imatinib 70 bevacizumab 70 cisplatin 70 Fludara 69 complete cytogenetic 69 azacitidine 69 methotrexate 69 peginterferon 68 decitabine 68 tyrosine kinase inhibitors 68 DMARD 68 temozolomide 68 azathioprine 68 mycophenolate mofetil 68 adalimumab 68 raltegravir 68 EGFR inhibitors 67 entecavir 67 TNF inhibitors 67 fulvestrant 67 tyrosine kinase inhibitor 67 TACE 67 interferon 67 FOLFOX 67 DMARDs 67 imatinib resistant 67 anti TNF 66 monotherapy 66 oxaliplatin 66 Dasatinib 66 adefovir 66 idarubicin 66 Gefitinib 66 anastrozole 66 FOLFOX4 66 mitoxantrone 66 Doxil ® 66 tamoxifen 66 NRTIs 66 irinotecan 66 metastatic renal cell carcinoma 66 anthracyclines 66 dacarbazine 66 FOLFIRI 66 fluconazole 66 vandetanib 66 chronic myeloid leukemia CML 66 AMN# [001] 66 carboplatin 66 metformin 66 APTIVUS r 65 pegylated liposomal doxorubicin 65 sorafenib Nexavar 65 tocilizumab 65 fludarabine 65 biologic therapy 65 imatinib mesylate 65 doxorubicin 65 complete cytogenetic response 65 temsirolimus 65 virologic failure 65 gefitinib Iressa 65 lapatinib 65 chemotherapy regimens 65 NNRTI 65 ribavirin RBV 65 docetaxel chemotherapy 65 pioglitazone 65 interferon alfa 65 TNF inhibitor 64 Gleevec resistant 64 Bortezomib 64 clodronate 64 oblimersen 64 NNRTIs 64 bendamustine 64 paclitaxel 64 chemotherapeutic agents 64 clopidogrel 64 imatinib mesylate Gleevec 64 heavily pretreated 64 dexamethasone 64 CHOP chemotherapy 64 leflunomide 64 pemetrexed 64 interferon alpha 64 Tasigna 64 cytogenetic response 64 protease inhibitor 64 Xeloda 64 etoposide 64 chronic lymphocytic leukemia CLL 64 VAPRISOL 64 chemoradiotherapy 64 Bevacizumab 64 carboplatin paclitaxel 64 Glivec 64 DFMO 64 SPRYCEL 64 5 FU 64 TKIs 64 bicalutamide 64 allopurinol 64 neoadjuvant chemotherapy 64 dasatinib Sprycel 64 capecitabine 64 alkylating agents 64 letrozole 64 bevacizumab Avastin ® 64 chemoradiation 64 aromatase inhibitor 63 DMARDS 63 lenalidomide 63 5FU 63 DOXIL 63 complete remissions 63 fluorouracil 63 sustained virologic response 63 disease modifying antirheumatic 63 mRCC 63 Herceptin trastuzumab 63 standard chemotherapy regimen 63 trabectedin 63 interferon therapy 63 cytogenetic responses 63 Amrubicin 63 virological failure 63 tipranavir 63 DAPT 63 cyclophosphamide 63 PegIFN RBV 63 metastatic RCC 63 mg kg dose 63 patients evaluable 63 erlotinib Tarceva ® 63 VICTRELIS 63 dose dexamethasone 63 bevacizumab Avastin 63 cytotoxic chemotherapy 63 pegylated interferon 63 chemotherapies 63 rhTSH 63 Erlotinib 63 CR nPR 63 anti leukemic 63 leucovorin 63 evaluable patients 63 calcitriol 63 VIDAZA 63 cytarabine 63 INTELENCE 63 pCR 63 G CSF 62 HER2 positive metastatic breast 62 Trastuzumab 62 Irinotecan 62 carvedilol 62 eplerenone 62 cetuximab Erbitux R 62 disease progression 62 mapatumumab 62 mutated KRAS 62 VIRAMUNE 62 erlotinib Tarceva 62 immunosuppressant 62 gastrointestinal stromal tumors 62 paricalcitol 62 vancomycin 62 leukemia AML 62 talabostat 62 panitumumab 62 ramipril 62 dexamethasone Decadron 62 clozapine 62 idraparinux 62 Ph + ALL 62 gemcitabine Gemzar 62 CCyR 62 Cisplatin 62 anthracycline 62 VFEND 62 nelfinavir 62 vinorelbine 62 cabazitaxel 62 taxanes 62 Nilotinib 62 pertuzumab 62 Vectibix 62 EGFR TKI 62 natalizumab 62 alkylating agent 62 CIMZIA TM 62 antiviral therapy 62 gastrointestinal stromal tumors GIST 62 Taxotere ® 62 plus dexamethasone 62 rapamycin 62 PLX# 62 heavily pretreated patients 62 standard chemotherapy regimens 62 imatinib Gleevec ® 62 median PFS 62 viral kinetics 62 tamoxifen therapy 62 recurrent GBM 62 SUTENT 62 Rituximab 62 darunavir 62 receiving VICTRELIS 62 glucocorticoids 61 adjuvant therapy 61 cisplatin chemotherapy 61 IFN alpha 61 T#I [002] 61 hydroxychloroquine 61 aliskiren 61 K ras mutations 61 intravenous bisphosphonates 61 NRTI 61 dasatinib Sprycel ® 61 anakinra 61 leukemia CLL 61 hematologic toxicity 61 lapatinib Tykerb 61 arsenic trioxide 61 ACE inhibitor 61 5 fluorouracil 61 enfuvirtide 61 bortezomib Velcade 61 ixabepilone 61 5-FU/LV 61 peginterferon alfa 2b 61 immunosuppressive agents 61 adriamycin 61 protease inhibitor PI 61 linezolid 61 fluvastatin 61 HAART 61 EGFR TKIs 61 Sprycel 61 Peg IFN 61 GnRH agonist 61 losartan 61 XELOX 61 PREZISTA r 61 relapsed ovarian cancer 61 daunorubicin 61 plus ribavirin 61 seliciclib 61 dexrazoxane 61 TYKERB 61 Aptivus ® 61 Gleevec imatinib 61 peginterferon alfa 2a 61 teriparatide 61 pegfilgrastim 61 HBeAg positive patients 61 Cytoxan 61 low dose cytarabine 61 ceftriaxone 61 pomalidomide 61 neoadjuvant therapy 61 caspofungin 61 relapsed refractory 61 placebo dexamethasone 61 EGFR tyrosine kinase inhibitors 61 ritonavir boosted 61 FTY# 61 octreotide LAR 61 chemotherapeutic agent 61 pegylated interferon alpha 61 EGFR mutations 61 nitazoxanide 61 antihypertensive therapy 61 amoxicillin clavulanate 61 virologic 61 immunomodulator 61 rituximab Rituxan 61 HCV infected 61 MabCampath 61 peginterferon alfa 61 methotrexate therapy 61 BEACOPP 61 thalidomide Thalomid 61 ipilimumab 61 chemotherapy regimen 61 chemotherapy docetaxel 61 FluCAM 61 corticosteroid therapy 61 pamidronate 61 Sorafenib 61 EGFR mutation 61 ribavirin 61 cetuximab Erbitux ® 61 amphotericin B 61 Rituxan 61 xenograft models 61 pancreatic adenocarcinoma 61 Taxotere 61 antihypertensive drugs 61 hormonal therapy 61 imipenem 61 nucleoside analogue 60 pregabalin 60 low dose dexamethasone 60 imetelstat 60 spironolactone 60 tyrosine kinase inhibitors TKIs 60 Everolimus 60 BARACLUDE ® 60 tolvaptan 60 liposomal doxorubicin 60 taxane therapy 60 Vandetanib 60 Tarceva 60 IFN beta 60 olmesartan 60 Alemtuzumab 60 bleomycin 60 virologic response 60 insulin glargine 60 LPV r 60 atazanavir 60 cell lymphoma CTCL 60 nucleoside analogues 60 tumor recurrence 60 alteplase 60 BMS # 60 neoadjuvant treatment 60 infusional 5-FU/LV 60 valsartan 60 TORISEL 60 angiotensin converting enzyme inhibitors 60 alfa 2a 60 pegylated interferon alfa 2b 60 abatacept 60 Kaplan Meier analysis 60 LHRH agonists 60 sulfasalazine 60 exemestane 60 imatinib resistance 60 estramustine 60 Iressa 60 FOLPI 60 Torisel 60 viral suppression 60 free survival PFS 60 EGFR inhibitor 60 chemotherapy gemcitabine 60 azacytidine 60 abiraterone 60 T#I mutation 60 pimecrolimus 60 protease inhibitors 60 efalizumab 60 androgen deprivation 60 tipifarnib 60 leukemia ALL 60 NNRTI resistance 60 interferon alfa 2b 60 CA4P 60 FOLFIRINOX 60 Kantarjian 60 Velcade 60 interferon ribavirin 60 TNFα 60 antiplatelet therapy 60 glatiramer acetate 60 Velcade bortezomib 60 evaluable 60 tipranavir ritonavir 60 nab paclitaxel 60 iniparib 60 candesartan 60 mCRC patients 60 surrogate endpoint 60 alefacept 60 adalimumab Humira 60 rFVIIa 60 Femara 60 telbivudine 60 statin 60 TNF antagonist 60 Mylotarg 60 posaconazole 60 response CCyR 60 BRAF mutation 60 celecoxib 60 cidofovir 60 ribavirin therapy 60 chronic myelogenous leukemia CML 60 mTOR inhibitors 60 antidepressant therapy 60 splenectomized patients 60 Cetuximab 60 HBeAg seroconversion 60 myeloablative 60 pegylated interferon alfa 60 galiximab 60 goserelin 60 B CLL 60 ZOLINZA 60 corticosteroids 60 vorinostat 60 Lenalidomide 60 Fludarabine 60 LEXIVA r 60 YONDELIS 60 CANCIDAS 60 Jevtana 60 Gemcitabine 60 Myelodysplastic Syndrome MDS 60 hypomethylating agents 60 Taxotere R 60 lupus nephritis 60 Hycamtin 60 lopinavir 60 aprepitant 59 IFN α 59 Valcyte 59 Capecitabine 59 voriconazole 59 liver metastases 59 neoadjuvant 59 irbesartan 59 inhaled steroids 59 statin therapy 59 CLL SLL 59 Hydroxyurea 59 beta interferon 59 omalizumab 59 bisphosphonate 59 Navelbine 59 follicular lymphoma 59 cyclosporine 59 Darunavir 59 tumor progression 59 fondaparinux 59 peg IFN 59 N acetylcysteine 59 LEXIVA 59 tiotropium 59 Gleevec imatinib mesylate 59 tyrosine kinase inhibitor TKI 59 HSCT 59 IGFBP 3 59 REMICADE ® 59 achieve sustained virologic 59 olaparib 59 risedronate 59 febrile neutropenia 59 leukemic cells 59 amrubicin 59 therapeutic regimens 59 angiotensin receptor blocker ARB 59 dose cytarabine 59 itraconazole 59 BARACLUDE 59 everolimus 59 ganciclovir 59 amprenavir 59 HuMax CD4 59 HAART regimen 59 abacavir lamivudine 59 antiangiogenic therapy 59 mg dose 59 tamsulosin 59 Zolinza 59 NSCLC 59 HBeAg 59 visilizumab 59 trimethoprim sulfamethoxazole 59 ACTEMRA 59 montelukast 59 adjuvant chemotherapy 59 chemotherapeutics 59 metastatic colorectal cancer 59 YERVOY 59 etravirine 59 mTOR inhibitor 59 receptor tyrosine kinase inhibitor 59 darunavir ritonavir 59 Tarceva erlotinib 59 cART 59 GnRH agonists 59 Targretin 59 L dopa 59 gastrointestinal stromal tumor GIST 59 tacrolimus 59 Traficet EN 59 refractory chronic myeloid 59 platinum refractory 59 enzastaurin 59 TKI therapy 59 advanced NSCLC 59 tenofovir emtricitabine 59 Combination therapy 59 KRAS status 59 tigecycline 59 log# reduction 59 statins 59 taxane chemotherapy 59 pDCs 59 Bcl xL 59 metastatic CRC 59 clopidogrel Plavix 59 ATACAND 59 anti TNFs 59 neurologic progression 59 lenalidomide Revlimid R 59 comparator PI r 59 Tykerb 59 KIT mutations 59 BAY #-# 59 preoperative chemotherapy 59 Sandostatin LAR 59 CsA 59 immunomodulatory therapy 59 KRAS mutations 59 ganetespib 59 quetiapine 59 nonresponders 59 partial remissions 59 ISENTRESS 59 Doxil 59 telaprevir dosed 59 gemcitabine chemotherapy 59 CellCept 59 sustained virological response 59 metastatic malignant 59 ponatinib 59 cilengitide 59 Peginterferon 59 Herceptin 59 endocrine therapy 59 PROMACTA 59 administered subcutaneously 59 citalopram 59 anthracycline therapy 59 taxane 59 sirolimus 59 romiplostim 59 bosutinib 59 pegylated interferon alfa 2a 59 typical antipsychotics 59 PegIntron 59 thalidomide dexamethasone 59 tumor shrinkage 59 antitumor effect 59 pazopanib 59 Docetaxel 59 refractory AML 59 5 Fluorouracil 59 ABC/3TC 59 sorafenib Nexavar ® 59 MAOI 59 alpha interferon 59 CLL cells 59 CR CRu 59 recurrent glioblastoma multiforme 59 eribulin 59 vicriviroc 59 ACE inhibitors 59 T DM1 59 leukemic stem cells 59 biochemical recurrence 59 angiotensin converting enzyme ACE 59 GVAX 59 EGFRvIII 59 alpha 2a 59 severe neutropenia 59 Fulvestrant 59 Paraplatin ® 59 Gemzar ® 59 IRESSA 59 LY# [003] 59 trans retinoic acid 59 lopinavir r 59 mg BID 59 angiogenesis inhibitor 58 relapsed MM 58 cinacalcet 58 HBeAg negative patients 58 TREANDA 58 panobinostat 58 piperacillin tazobactam 58 follicular NHL 58 OADs 58 achieved sustained virological 58 CMV infection 58 progression TTP 58 prior chemotherapy regimens 58 neostigmine 58 hypercalcemia 58 Bcr Abl mutations 58 conventional DMARDs 58 BCR ABL 58 ACTEMRA TM 58 cediranib 58 interferon beta 58 HGS ETR1 58 OPAXIO 58 TELCYTA 58 sunitinib Sutent ® 58 COPAXONE R 58 cisplatin resistant 58 interferon IFN 58 cholinesterase inhibitor 58 Pegasys ® 58 calcineurin inhibitors 58 mcg kg 58 GRK2 58 alendronate 58 certolizumab 58 DMARD therapy 58 Interferon 58 immunosuppression 58 XGEVA 58 isoproterenol 58 TNFa 58 bezafibrate 58 epirubicin 58 #mg dose [001] 58 eosinophilic asthma 58 Tamibarotene 58 ibandronate 58 biochemical relapse 58 Folfox 58 CTLA 4 58 hydroxyurea 58 remission induction 58 TTR gene 58 axitinib 58 β blockers 58 glucocorticoid 58 anticancer therapies 58 cyclosporin 58 docetaxel Taxotere 58 isoniazid 58 maraviroc 58 RGT arm 58 nucleoside analogs 58 Laquinimod 58 tenofovir DF 58 rasagiline 58 malignant pleural mesothelioma 58 irinotecan chemotherapy 58 Exemestane 58 relapsed SCLC 58 intravenous cyclophosphamide 58 allogeneic SCT 58 virological response 58 chemotherapeutic drug 58 6 mercaptopurine 58 TOP2A 58 zalutumumab 58 Ribavirin 58 Xanafide 58 proteasome inhibitors 58 LMWH 58 telmisartan 58 depsipeptide 58 IFN gamma 58 EGFR 58 comparator arm 58 histone deacetylases 58 SCH # 58 intravesical 58 abciximab 58 mg/m2 dose 58 ZD# [001] 58 HAART regimens 58 adjuvant tamoxifen 58 AZT zidovudine Retrovir 58 Taxol 58 melphalan prednisone 58 gemcitabine cisplatin 58 endostatin 58 SCCHN 58 ACZ# 58 anticancer therapy 58 fibrinolytic 58 Pemetrexed 58 MetMAb 58 peginterferon alfa 2a #KD 58 virologically 58 xanthine oxidase inhibitor 58 Epivir 58 relapsed CLL 58 achieved sustained virologic 58 proteasome inhibitor 58 octreotide 58 TZDs 58 Doxorubicin 58 lenalidomide dexamethasone 58 flutamide 58 HBV DNA 58 colorectal liver metastases 58 milatuzumab 58 chemotherapy 58 sertraline 58 levofloxacin 58 EGFr 58 dalteparin 58 VEGF inhibitors 58 ketoconazole 58 gliclazide 58 CMV disease 58 dose clopidogrel 58 glioblastoma 58 verteporfin 58 PEGINTRON 58 metastatic kidney 58 Anthracycline 58 severe psoriasis 58 insulin detemir 58 nucleoside reverse transcriptase inhibitor 58 castration resistant prostate cancer 58 Revlimid 58 levodopa 58 Genasense 58 REYATAZ r 58 refractory CLL 58 BRAF mutations 58 Zoledronic acid 58 steroid dexamethasone 58 imiquimod 58 Hepsera 58 interferon alfa 2a 58 captopril 58 pyrazinamide 58 antiandrogen 58 immunosuppressive 58 MCyR 58 Cyclosporine 58 VELCADE 58 CCR5 antagonist 58 trastuzumab Herceptin 58 Flu Cy 58 Interferon alfa 58 anthracycline taxane 58 sorafenib tablets 58 platelet reactivity 58 GISTs 58 VEGFR2 58 Clolar 58 docetaxel Taxotere ® 58 IGF 1R 58 achieved ACR# 58 capecitabine Xeloda 58 lipid lowering therapy 58 PXD# 58 ZYVOX 58 Vidaza 58 dacetuzumab 58 Halaven 58 interferon beta therapy 58 rizatriptan 58 gastrointestinal stromal tumor 58 multidrug resistance 57 MYLOTARG 57 immunosuppressant drug 57 seropositive patients 57 ELOXATIN 57 CIMZIA ™ 57 Tarceva TM 57 relapsing remitting multiple sclerosis 57 fibrinolytic therapy 57 lipid lowering drugs 57 EGFR antibodies 57 EBRT 57 TNF antagonists 57 active comparator 57 paroxysmal AF 57 chemotherapeutic regimens 57 teriflunomide 57 eptifibatide 57 limiting toxicity 57 indolent NHL 57 KRAS wild 57 DAS# remission 57 Bezielle 57 HCV genotypes 57 distant metastasis 57 antihypertensive agents 57 zolmitriptan 57 azoles 57 amiodarone 57 GVHD 57 Glivec imatinib 57 hormonal therapies 57 TMC# [001] 57 clinically meaningful differences 57 achieved CCyR 57 Celecoxib 57 fosamprenavir 57 nortriptyline 57 CYT# 57 Telintra 57 vWF 57 nucleoside 57 perifosine 57 Hycamtin ® 57 oral clodronate 57 trabedersen 57 immunosuppressive therapies 57 tenofovir Viread 57 INCB# [001] 57 AZILECT 57 Campath alemtuzumab 57 anticholinergics 57 TDF FTC 57 bosentan 57 ustekinumab 57 palifermin 57 efavirenz 57 Sutent 57 radiographic progression 57 d4T 57 LT NS# 57 estrogen receptor beta 57 Raltegravir 57 GBM tumors 57 quinolone 57 Aromasin 57 FOLFIRI alone 57 toxicities 57 MEK inhibitors 57 venlafaxine 57 distant metastases 57 antiretroviral regimens 57 Taxol paclitaxel 57 androgen suppression 57 ertapenem 57 boosted protease inhibitor 57 HER2 positive 57 sunitinib malate 57 Platinol 57 Hodgkin lymphoma NHL 57 evaluable subjects 57 ticagrelor 57 SPRYCEL ® 57 Elitek 57 pitavastatin 57 sitagliptin 57 PREZISTA rtv 57 selegiline 57 Zometa 57 lamotrigine 57 CoFactor 57 elotuzumab 57 trastuzumab Herceptin ® 57 peg interferon 57 budesonide 57 cilostazol 57 rosuvastatin 57 FOLFOX6 57 clusterin 57 motesanib 57 anti androgen 57 lopinavir ritonavir 57 forskolin 57 ULORIC 57 cetuximab Erbitux 57 locoregional 57 unresectable 57 metastatic lung cancer 57 Neoadjuvant 57 Infliximab 57 relapsed multiple myeloma 57 calcineurin inhibitor 57 micafungin 57 cystectomy 57 potent antiviral 57 metastatic GIST 57 GRN#L 57 antitumor activity 57 pravastatin 57 mcg dose 57 bisphosphonate therapy 57 thromboembolic events 57 Azacitidine 57 anidulafungin 57 degarelix 57 fluticasone 57 panitumumab Vectibix 57 remission CR 57 Taxol ® 57 PKC# 57 methotrexate monotherapy 57 dutasteride 57 antiretroviral therapy 57 pegylated liposomal doxorubicin PLD 57 esomeprazole 57 immunosuppressive drugs 57 Campath 57 BH4 57 Atacand 57 REYATAZ 57 metastatic melanoma 57 abiraterone acetate 57 APTIVUS 57 REVLIMID 57 luteinizing hormone releasing 57 paclitaxel Taxol 57 INCB# [003] 57 cis retinoic acid 57 fluoropyrimidine 57 GRASPA ® 57 miglustat 57 Degarelix 57 T#I mutant 57 antiangiogenic 57 aripiprazole 57 nicardipine 57 sunitinib Sutent 57 Immunohistochemical analysis 57 antiepileptic drugs AEDs 57 efavirenz Sustiva 57 relapsed AML 57 prospectively defined 57 Adalimumab 57 Pharmacokinetics PK 57 amlodipine 57 mitoxantrone chemotherapy 57 antipsychotic 57 AGILECT R 57 eltrombopag 57 nilotinib Tasigna ® 57 follicular lymphomas 57 LHRH 57 BYSTOLIC 57 superficial bladder cancer 57 Revlimid lenalidomide 57 FOXP3 57 ERBITUX 57 cyclin E 57 chloroquine 57 plus gemcitabine 57 MGd 57 STELARA 57 pancreatic neuroendocrine tumors 57 Avastin 57 basiliximab 57 paclitaxel carboplatin 57 durable remissions 57 Interferon alpha 57 deferoxamine 57 chemotherapeutic drugs 57 Etanercept 57 valproate 57 myelodysplastic syndrome MDS 57 Bcr Abl inhibitors 57 RECIST criteria 57 zoledronate 57 ENBREL 57 bone metastasis 57 pimozide 57 Sprycel dasatinib 57 androgen therapy 57 ALK inhibitor 57 IMGN# 57 Mitoxantrone 57 NMIBC 57 Copegus ribavirin 57 minocycline 57 Leukine 57 ximelagatran 57 HCV RNA 57 plasma uric acid 57 TNF α 57 flavopiridol 57 nephrotoxicity 57 granisetron 57 nilotinib Tasigna 57 rituximab monotherapy 57 CBLC# 57 plus prednisone